Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

Long-term use of common anti-acid medications, known as proton pump inhibitors (PPIs), may not increase the risk of stomach ...

In attempt to assess treatment patterns in advanced gastric cancer across racial and ethnic groups throughout the U.S., ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. The updated data ...

Proton pump inhibitors are among the most commonly prescribed medications worldwide, but concerns about a possible link to stomach cancer have lingered for decades. Proton pump inhibitors (PPIs) are a ...

Objective To help to clarify whether long term use of proton pump inhibitors is associated with an increased risk of gastric adenocarcinoma by designing a study that considered the existing literature ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of ...

In a recent phase III randomized controlled trial (RCT) published in The Lancet Regional Health – Europe, researchers from the Netherlands investigated and compared the long-term weight loss effects ...